Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 181

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 181
---
 technology and the purchased intellectual property is expected to be amortized over the next 2.0 years, approximately. As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):  

        2025
         
        $
        1,699

        2026

        1,699

        2027

        27

        Total future amortization expense
         
        $
        3,425

107

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

9.Accrued LiabilitiesAccrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands): 

        December 31,

        2024

        2023

        Professional fees
         
        $
        2,922

        $
        4,920

        Clinical and contract research organization costs

        874

        863

        Travel and entertainment

        202

        154

        Tax liabilities

        176

        59

        Purchases of property and equipment

        88

        687

        Computer and software

        3,065

        1,151

        Other

        830

        763

        Total accrued liabilities
         
        $
        8,157

        $
        8,597

10.LeasesWe have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations. In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years. The amended lease also requires us to pay additional amounts for operating and maintenance expenses.In 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount